Eli Lilly
By therapeutic area
| Therapeutic area | Premium | Deals |
|---|---|---|
| oncology | ×1.16 | 20 |
By stage at signing
| Phase | Premium | Deals |
|---|---|---|
| approved | ×1.22 | 7 |
| phase 3 | ×1.01 | 5 |
| phase 2 | ×1.07 | 4 |
| discovery | ×0.70 | 4 |
| preclinical | ×1.50 | 4 |
Strategy profile
Based on 15 disclosed transactions, Eli Lilly concentrates its licensing activity in Mega Deals, Neurology, and Oncology. Eli Lilly pays a 1.09x premium over market median, with the strongest premiums in Oncology (1.16x). Their most common deal structure is Collaboration, with an average disclosed value of $2.2B. Most recent activity: 2026.
Premium by therapeutic area
How Eli Lilly pays relative to peer medians in each TA
Pipeline coverage & gaps
Eli Lilly has disclosed activity in 1 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| CollaborationPrimary | 7 | $42M | $2.2B |
| Acquisition | 4 | $6.3B | $3.3B |
| License | 4 | $75M | $1.1B |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2026 | vaccine candidates and platforms | LimmaTech Biologics | infectious diseases | unknown | — | $2.3B |
| 2026 | in vivo CAR-T platform | Orna Therapeutics | oncology | unknown | — | $2.4B |
| 2026 | Ajax oncology platform | Ajax Therapeutics | — | unknown | — | $2.3B |
| 2026 | AI-driven drug discovery multi-target collaboration | Insilico Medicine | — | discovery | — | $2.8B |
| 2026 | multitarget oncology programs | Abbisko | oncology | discovery | — | $1.9B |
| 2026 | cleminorexant | Centessa Pharmaceuticals | narcolepsy and idiopathic hypersomnia | unknown | $6.3B | $6.3B |
| 2026 | RNA exon-editing kidney disease program | Ascidian Therapeutics | genetic kidney diseases | discovery | — | $1.9B |
| 2026 | Ajax collaboration program | Ajax | — | unknown | — | $2.3B |
| 2026 | RNA exon-editing programs (genetic kidney diseases) | Ascidian | genetic kidney diseases | unknown | — | $1.9B |
| 2026 | AlzeCure Alzheimer's asset | AlzeCure Pharma | Alzheimer's disease | unknown | — | $1.0B |
| 2026 | AlzeCure Alzheimer's candidate | AlzeCure Pharma | Alzheimer's disease | preclinical | — | $1.0B |
| 2026 | gamma-secretase modulator for Alzheimer's | AlzeCure | Alzheimer's disease | unknown | — | $1.0B |
| 2026 | RNA exon-editing candidates | Ascidian Therapeutics | genetic diseases / neurological monogenic disorders | preclinical | $42M | $1.9B |
| 2026 | sonefpeglutide | Hanmi Pharm | short bowel syndrome | phase_2 | $75M | $1.2B |
| 2026 | Haisco collaboration program | Haisco | — | unknown | — | $3.0B |
How this is computed
For each Eli Lilly deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 26 disclosed deal premiums vs. peer medians. Raw premium 1.090, clamped to [0.7, 1.5].